Wechselwirkungen · Sitagliptin / Metformin hydrochloride Mylan
Sitagliptin/Metformin hydrochloride Mylan 50 mg/850 mg film-coated tablets Sitagliptin/Metformin hydrochloride Mylan 50 mg/1,000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-148477 · Präparat HOS-099918
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8. In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin. Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end- stage renal disease (ESRD). For this reason, it is possible that potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the pharmacokinetics of sitagliptin in patients with severe renal impairment or ESRD. The effects of potent CYP3A4 inhibitors in the setting of renal impairment have not been assessed in a clinical study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521) sitagliptin (HOS-117222)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T15:00:00Z · SHA-256 7f7902cef3cb0d8682217ccaea7e82e0a4ba4110a01fb5305737dce34edcb3a4 · Passage cbf4a1b3499a510f11f4774254476e1c997513de3f8d2391e0b25cc72de10dcc · Zeichen 2941–3715 im Abschnitt